The FDA recently approved the new diabetes medication Rybelsus to manage type 2 diabetes. This is an important step since before Rybelsus, the medication was only available as an injection. Similar glucagon-like peptide-1s (GLP-1s) that are available by injection are Trulicity, Byetta, Bydureon, Victoza, and Ozempic.
What do you need to know about Rybelsus?
Rybelsus is part of a drug class known as GLP-1 agonists. Novo Nordisk is releasing this pill following up on its injectable medication liraglutide (Victoza, Ozempic). This semaglutide pill was approved after trials in 9,500 type 2 patients. The drug was shown to be effective in reducing weight, reducing heart attack risk, and controlling blood glucose levels better than other drugs on the market. Rybelsus has the potential to be used to treat fatty liver inflammation as well.
How does it work?
Rybelsus is taken once daily. It works by keeping the liver from producing too much sugar, thus increasing insulin levels and decreasing glucagon levels. It can also help reduce appetite and slow down digestion. Maintaining a healthy weight is an important aspect of managing type 2 diabetes.
Risks of Rybelsus
Possible side effects of this diabetes medication are inflammation of the pancreas, vision loss, drop in blood sugar, and kidney injury. The most common side effects are nausea, diarrhea, vomiting, low appetite, indigestion, and constipation.